• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, May 25

RPG Life Sciences Ltd (RPGLSL) has received an Australian patent for its novel formulation of cyclosporin, an immunosuppresant used in patients that have undergone transplants. The patent would allow RPGLSL to market the cyclosporin formulation in Australia and the drug has a global market of more than $1.2 billion.

RPGLSL is already marketing the formulation in India, besides some export markets.

The company has already received a patent for the cyclosporin formulation in South Africa, a note from the company said. RPG Life Sciences Ltd is the pharmaceutical arm of the Rs 9,500 crore RPG Group. RPGLSL shares were down 5.69 percent on the BSE at Rs 141.

More Stories on : IPR | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Focus Energy discovers gas in Rajasthan

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line